- Recall the signs and symptoms of bacterial pneumonia
- Describe the management of bacterial pneumonia
- Summarize the nursing diagnosis of pneumonia
- Discuss the prevention of bacterial pneumonia
The word "pneumonia" originates from the ancient Greek word "pneumon" which means "lung," so the word "penumonia" becomes "lung disease." Medically it is an inflammation of one or both lung's parenchyma that is more often but not always caused by infections. The many causes of pneumonia include bacteria, viruses, fungi, and parasites. This article is about bacterial causes of pneumonia as it is the major cause of mortality and morbidity by pneumonia. According to the new classification of pneumonia, there are four categories: community-acquired (CAP), hospital-acquired (HAP), healthcare-associated (HCAP) and ventilator-associated pneumonia (VAP). 
Types of Bacterial Pneumonia
Some articles include both HAP and VAP under the category of HCAP, so defining HCAP is problematic and controversial.
Etiology of community-acquired pneumonia is an extensive list of agents that include bacteria, viruses, fungi, and parasites, but this article is about bacterial pneumonia and its causes. Bacteria have classically been categorized into two divisions on the basis of etiology, "typical" and "atypical" organisms. Typical organisms can be cultured on standard media or seen on Gram stain, but "atypical" organisms do not have such properties. 
The most common causes of community-acquired pneumonia (CAP) is S. pneumoniae followed by Klebsiella pneumoniae, Haemophilus influenzae, and Pseudomonas aeruginosa. The most common causes of HCAP and HAP are MRSA (methicillin-resistant Staphylococcus aureus) and Pseudomonas aeruginosa respectively. The causative agents of VAP include both multi-drug resistant (MDR) agents (e.g., S. pneumoniae, other Strep spp, H. influenzae and MSSA) and non-MDR (e.g., P. aeruginosa, methicillin-resistant Staphylococcus aureus, Acinetobacter spp. and antibiotic-resistant Enterobacteriaceae) bacterial pathogens.
The incidence of CAP in the United States is more than 5 million per year; 80% of these new cases are treated as outpatients with the mortality rate of less than 1%, and 20% are treated as inpatients with the mortality rate of 12% to 40%. The incidence of CAP varies among different genders; for example, it is more common in males and African Americans than females and other Americans. The incidence rates are higher at extremes of age distribution range; the adult rate is usually 5.15 to 7.06 cases per 1000 persons per year, but in the population of age less than 4 years and greater than 60 years, the rate is more than 12 cases per 1000 persons. In 2005, influenza and pneumonia combined was the eighth most common cause of death in the United States and the seventh Most common cause of death in Canada. The mortality rate also is variable among different regions at 7.3% for the United States and Canada, 9.1% for Europe, and 13.3% for Latin America.
The history findings of bacterial pneumonia may vary from indolent to fulminant. Clinical manifestation includes both constitutional findings and findings due to damage to the lung and related tissue. The following are major history findings:
Physical findings also vary from patient to patient and mainly depend on the severity of lung consolidation and existence or nonexistence of pleural effusion. The following are major clinical findings:
Confusion manifests earlier in older patients. A critically ill patient may present with sepsis or multi-organ failure.
The approach to evaluate and diagnose pneumonia depends on different modalities but primarily it is like a tripod stand which has 3 legs which are summed up as:
In all patients with bacterial pneumonia, empirical therapy should be started as soon as possible. The first step in treatment is a risk assessment to know whether the patient should be treated in an outpatient or inpatient setting. Cardiopulmonary conditions, age, and severity of symptoms affect risk for bacterial pneumonia, especially CAP.
An expanded CURB-65 or CURB-65 pneumonia severity score can be used for risk quantification. It includes C = Confusion, U = Uremia (BUN greater than 20 mg/dL), R = Respiratory rate (greater than 30 per min), B = B.P (BP less than 90/60 mmHg) and age greater than 65 years. One point is scored for each previously mentioned risk factor. If the total of the score is 2 or more than 2, it indicates hospital admission. If the total is 4 or more than 4, it indicates ICU admission. Recommended therapy for different settings are as follows:
After getting a culture-positive lab result, therapies should be directed to the culture-specific pathogen.
The patient also can benefit from smoking cessation counseling and influenza and pneumococcal vaccination.
All patients treated at home should be scheduled for a follow-up visit within 2 days to assess any complication of pneumonia.
The management of a pneumonia is multidisciplinary. Besides the administration of antibiotics, these patients often require chest physical therapy, a dietary consult, physical therapy to help regain muscle mass and a dental consult. The key is to educate the patient on discontinuation of smoking and abstaining from alcohol. Further, patients should be encouraged to get the appropriate influenza and pneumococcal vaccines. Finally, it is important to educate the patient on compliance with antibiotics if they want a complete resolution of the infectious process. (Level V)
In healthy people, the outcome after a bacterial pneumonia is excellent. However, in people with advanced age, lung disease, immunosuppression, infection with aggressive gram-negative organisms (Klebsiella) and other comorbidities, the outcomes are usually poor. When a pneumonia is left untreated, it carries a mortality in excess of 25%. Pneumonia can also lead to extensive lung damage and lead to residual impairment in lung function. Other reported complications of pneumonia that occur in 1-5% of patients include lung abscess, empyema, and bronchiectasis. (Level V)
Call a physician if:
The management of pneumonia is with an interprofessional team. The reason is that most patients are managed as outpatients but if not properly treated, the morbidity and mortality are high.
Besides the administration of antibiotics, these patients often require chest physical therapy, a dietary consult, physical therapy to help regain muscle mass and a dental consult. The key is to educate the patient on the discontinuation of smoking and abstaining from alcohol.
Patients need to be referred to a dietitian to ensure that they are eating healthy.
Further, the clinicians should encourage patients to get appropriate influenza and pneumococcal vaccines. The pharmacist should not only teach about antibiotic compliance but ensure that the patient is prescribed the right antibiotics aimed at the target organism.
Leung AK,Hon KL,Leong KF,Sergi CM, Measles: a disease often forgotten but not gone. Hong Kong medical journal = Xianggang yi xue za zhi. 2018 Sep 24 [PubMed PMID: 30245481]
Grief SN,Loza JK, Guidelines for the Evaluation and Treatment of Pneumonia. Primary care. 2018 Sep [PubMed PMID: 30115336]
Calik S,Ari A,Bilgir O,Cetintepe T,Yis R,Sonmez U,Tosun S, The relationship between mortality and microbiological parameters in febrile neutropenic patients with hematological malignancies. Saudi medical journal. 2018 Sep [PubMed PMID: 30251730]
Mizgerd JP, Acute lower respiratory tract infection. The New England journal of medicine. 2008 Feb 14 [PubMed PMID: 18272895]
Kung HC,Hoyert DL,Xu J,Murphy SL, Deaths: final data for 2005. National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System. 2008 Apr 24 [PubMed PMID: 18512336]
Shin EJ,Kim Y,Jeong JY,Jung YM,Lee MH,Chung EH, The changes of prevalence and etiology of pediatric pneumonia from National Emergency Department Information System in Korea, between 2007 and 2014. Korean journal of pediatrics. 2018 Sep [PubMed PMID: 30274507]
Lat I,Daley MJ,Shewale A,Pangrazzi MH,Hammond D,Olsen KM, A Multicenter, Prospective, Observational Study to Determine Predictive Factors for Multidrug-Resistant Pneumonia in Critically Ill Adults: The DEFINE Study. Pharmacotherapy. 2018 Aug 12 [PubMed PMID: 30101412]
Søndergaard MJ,Friis MB,Hansen DS,Jørgensen IM, Clinical manifestations in infants and children with Mycoplasma pneumoniae infection. PloS one. 2018 [PubMed PMID: 29698412]
Karakuzu Z,Iscimen R,Akalin H,Kelebek Girgin N,Kahveci F,Sinirtas M, Prognostic Risk Factors in Ventilator-Associated Pneumonia. Medical science monitor : international medical journal of experimental and clinical research. 2018 Mar 5 [PubMed PMID: 29503436]
Phillips-Houlbracq M,Ricard JD,Foucrier A,Yoder-Himes D,Gaudry S,Bex J,Messika J,Margetis D,Chatel J,Dobrindt U,Denamur E,Roux D, Pathophysiology of Escherichia coli pneumonia: Respective contribution of pathogenicity islands to virulence. International journal of medical microbiology : IJMM. 2018 Mar [PubMed PMID: 29325882]
van der Poll T,Opal SM, Pathogenesis, treatment, and prevention of pneumococcal pneumonia. Lancet (London, England). 2009 Oct 31 [PubMed PMID: 19880020]
Claudius I,Baraff LJ, Pediatric emergencies associated with fever. Emergency medicine clinics of North America. 2010 Feb [PubMed PMID: 19945599]
Knaus WA,Draper EA,Wagner DP,Zimmerman JE, APACHE II: a severity of disease classification system. Critical care medicine. 1985 Oct [PubMed PMID: 3928249]
Kang YA,Kwon SY,Yoon HI,Lee JH,Lee CT, Role of C-reactive protein and procalcitonin in differentiation of tuberculosis from bacterial community acquired pneumonia. The Korean journal of internal medicine. 2009 Dec [PubMed PMID: 19949732]
Franquet T, Imaging of Community-acquired Pneumonia. Journal of thoracic imaging. 2018 Sep [PubMed PMID: 30036297]
Ayede AI,Kirolos A,Fowobaje KR,Williams LJ,Bakare AA,Oyewole OB,Olorunfemi OB,Kuna O,Iwuala NT,Oguntoye A,Kusoro SO,Okunlola ME,Qazi SA,Nair H,Falade AG,Campbell H, A prospective validation study in South-West Nigeria on caregiver report of childhood pneumonia and antibiotic treatment using Demographic and Health Survey (DHS) and Multiple Indicator Cluster Survey (MICS) questions. Journal of global health. 2018 Dec [PubMed PMID: 30254744]
Hanretty AM,Gallagher JC, Shortened Courses of Antibiotics for Bacterial Infections: A Systematic Review of Randomized Controlled Trials. Pharmacotherapy. 2018 Jun [PubMed PMID: 29679383]
Julián-Jiménez A,Adán Valero I,Beteta López A,Cano Martín LM,Fernández Rodríguez O,Rubio Díaz R,Sepúlveda Berrocal MA,González Del Castillo J,Candel González FJ, [Recommendations for the care of patients with community-acquired pneumonia in the Emergency Department]. Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia. 2018 Apr [PubMed PMID: 29619807]
Cillóniz C,Ewig S,Polverino E,Marcos MA,Esquinas C,Gabarrús A,Mensa J,Torres A, Microbial aetiology of community-acquired pneumonia and its relation to severity. Thorax. 2011 Apr [PubMed PMID: 21257985]
Coon ER,Maloney CG,Shen MW, Antibiotic and Diagnostic Discordance Between ED Physicians and Hospitalists for Pediatric Respiratory Illness. Hospital pediatrics. 2015 Mar [PubMed PMID: 25732983]
Bickenbach J,Schöneis D,Marx G,Marx N,Lemmen S,Dreher M, Impact of multidrug-resistant bacteria on outcome in patients with prolonged weaning. BMC pulmonary medicine. 2018 Aug 20 [PubMed PMID: 30126392]